Cryoport Downgraded to Sell as Valuation Outruns Profitability

What happened

Seeking Alpha downgraded Cryoport from Hold to Sell, citing valuation concerns despite strong revenue growth, and our own analysis aligns with this view. The company's balance sheet improved after the CRYOPDP sale, leaving net cash of $204.8 million, but profitability remains elusive. Revenue outperformed forecasts, driven by Life Sciences Services and commercial cell/gene therapy, yet net losses widened and margins stayed weak. Our deep-value assessment shows a negative DCF intrinsic value, implying no margin of safety at the current $9.70 share price. The stock's ~25% rebound over the past year appears to have priced in a successful turnaround that has not yet materialized.

Implication

Persistent net losses and negative interest coverage make the equity a speculative bet on cell and gene therapy scale-up, with limited downside protection beyond the cash cushion. The market capitalization of ~$473 million is supported primarily by optimism, as a DCF on recent cash flows yields a negative intrinsic value. While the $421 million cash and investment balance provides time, ongoing cash burn and the need for continued investment in infrastructure could erode this buffer without a clear path to breakeven. Key monitoring points include sustained improvement in adjusted EBITDA toward positive territory, acceleration in commercial CGT revenue, and evidence of operating leverage. Until these milestones are met, the risk/reward skews unfavorably, supporting a sell or avoid stance.

Thesis delta

Our previous stance was WAIT, contingent on execution and timing of profitability inflection. The downgrade to Sell, combined with our analysis showing widening net losses and a negative DCF, indicates that the market has overpriced the turnaround potential. We therefore shift to SELL, believing the current valuation lacks fundamental support and downside risk outweighs potential upside.